Evidence map›Paper›PMID 26309504›Full record

ArticleInternational journal of clinical and experimental medicine2015

Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: a meta-analysis of literatures.

Hongyu Kong, Qiongwen Zhang, Yunhui Zeng, Hong Wang, Mengqian Wu, Tianying Zheng, Yanzhang Zeng, Huashan Shi

Abstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Hongyu KongClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Qiongwen ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medicine School, Sichuan University Chengdu, Sichuan, PRC ; State Key Laboratory of Biotherapy and Department of Head and Neck Oncology, West China Hospital, West China Medical School, Sichuan University Chengdu, Sichuan, PRC.
Yunhui ZengClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Hong WangClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Mengqian WuClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Tianying ZhengClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Yanzhang ZengClinical Medicine (Eight-Year Program), West China School of Medicine, Sichuan University Chengdu, Sichuan, PRC.
Huashan ShiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medicine School, Sichuan University Chengdu, Sichuan, PRC ; State Key Laboratory of Biotherapy and Department of Head and Neck Oncology, West China Hospital, West China Medical School, Sichuan University Chengdu, Sichuan, PRC.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe prognostic value of the expression of STAT3/phosphorylated-STAT3 on survival for cancer patients remains controversial. We performed a meta-analysis of the published literature in this field to identify its impact.

methodsWe conducted a meta-analysis of 26 studies (n=3877 patients) that evaluated the relationship between the prognostic value and the expression of STAT3/phosphorylated-STAT3 in 15 different kinds of carcinomas. Studies evaluated the correlation between STAT3/phosphorylated-STAT3, which detected mostly by immunohistochemistry and western blot, and clinical staging, overall survival (OS) and disease free survival (DFS) were included. The impact of STAT3 and phosphorylated-STAT3 was analyzed separately.

resultsA total of 26 studies (14 for STAT3 and 16 for phosphorylated-STAT3), comprising 3877 patients, were included for meta-analysis. The expression of STAT3 was strongly associated with a poor impact on overall survival (OS) in all eligible studies [hazard ratio (HR)=2.91, (95% confidence interval (CI), 1.91-4.42)], while a significant association was shown between the expression of phosphorylated-STAT3 and patients' outcome [HR=1.53, (95% CI, 0.86-2.70)]. No significant effect was shown between the expression of STAT3/phosphorylated-STAT3 and clinical staging, neither with DFS.

conclusionHigh expression of STAT3 seems to be associated with poor OS in patients with carcinomas, while phosphorylated-STAT3 does not.

Indexed as

Meta-analysisprognosisSTAT3/phosphorylated-STAT3tumor

Identifiers

PMID26309504
PMCPMC4537978
OpenAlexW2474424660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.